Skip to main content

MYOBLOTS PARA LA EVALUACION RAPIDA DE NUEVOS TRATAMIENTOS PARA LA DISTROFIA MIOTONICA.

PI18/00114

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre ASOCIACION INSTITUTO DE INVESTIGACION SANITARIA BIOCRUCES BIZKAIA
Execution centre BIOCRUCES HEALTH RESEARCH INSTITUTE (IIS BIOCRUCES)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I

  • López-Martínez, Andrea|||0000-0003-4711-7495
  • Soblechero-Martín, Patricia
  • de-la-Puente-Ovejero, Laura|||0000-0002-0835-7069
  • Nogales, Gisela|||0000-0002-7414-212X
  • Arechavala-Gomeza, Virginia|||0000-0001-7703-3255
Myotonic dystrophy type I (DM1) is the most common form of adult muscular dystrophy, caused by expansion of a CTG triplet repeat in the 3' untranslated region (3'UTR) of the myotonic dystrophy protein kinase (DMPK) gene. The pathological CTG repeats result in protein trapping by expanded transcripts, a decreased DMPK translation and the disruption of the chromatin structure, affecting neighboring genes expression. The muscleblind-like (MBNL) and CUG-BP and ETR-3-like factors (CELF) are two families of tissue-specific regulators of developmentally programmed alternative splicing that act as antagonist regulators of several pre-mRNA targets, including troponin 2 (TNNT2), insulin receptor (INSR), chloride channel 1 (CLCN1) and MBNL2. Sequestration of MBNL proteins and up-regulation of CELF1 are key to DM1 pathology, inducing a spliceopathy that leads to a developmental remodelling of the transcriptome due to an adult-to-foetal splicing switch, which results in the loss of cell function and viability. Moreover, recent studies indicate that additional pathogenic mechanisms may also contribute to disease pathology, including a misregulation of cellular mRNA translation, localization and stability. This review focuses on the cause and effects of MBNL and CELF1 deregulation in DM1, describing the molecular mechanisms underlying alternative splicing misregulation for a deeper understanding of DM1 complexity. To contribute to this analysis, we have prepared a comprehensive list of transcript alterations involved in DM1 pathogenesis, as well as other deregulated mRNA processing pathways implications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I

  • Koehorst, Emma
  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Arechavala-Gomeza, Virginia|||0000-0001-7703-3255
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
MicroRNAs (miRNAs) are mostly known for their gene regulation properties, but they also play an important role in intercellular signaling. This means that they can be found in bodily fluids, giving them excellent biomarker potential. Myotonic Dystrophy type I (DM1) is the most frequent autosomal dominant muscle dystrophy in adults, with an estimated prevalence of 1:8000. DM1 symptoms include muscle weakness, myotonia, respiratory failure, cardiac conduction defects, cataracts, and endocrine disturbances. Patients display heterogeneity in both age of onset and disease manifestation. No treatment or cure currently exists for DM1, which shows the necessity for a biomarker that can predict disease progression, providing the opportunity to implement preventative measures before symptoms arise. In the past two decades, extensive research has been conducted in the miRNA expression profiles of DM1 patients and their biomarker potential. Here we review the current state of the field with a tissue-specific focus, given the multi-systemic nature of DM1 and the intracellular signaling role of miRNAs.